anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Bariatric surgery is the most effective treatment for people with obesity. It has been shown that there's is a complex psychosocial overlay in the pathophysiology and treatment, which requires specific consideration when delivering care. There is a significant drop out rate for patients accepted on to bariatric programmes in New Zealand, resulting in failure to progress to surgical intervention.
METHODS: We conducted individual, semi-structured interviews with patients who were accepted onto the bariatric surgery programme but did not complete the programme, or receive an operation between 2015 and 2020. Grounded theory methodology was used to create an exploratory framework to identify and describe the themes encountered. An iterative process of thematic analysis and comparison between participants experiences was used to consolidate the shared key barriers. This study aims to explore patients experiences of a bariatric surgery programme to understand barriers and enablers to complete a bariatric programme and receive an operation. Adding to previous qualitative work investigating patients experience of bariatric surgery programmes in New Zealand.
RESULTS: Five themes of barriers that patients face to receiving bariatric surgery were identified. These were preoperative weight loss requirement, experiencing the social stigma of obesity, communication, socioeconomic and geographic barriers, and community support. These five themes often co-exist in patients experiences and combine, to cause patients to disengage with the bariatric service.
CONCLUSION: Many factors contribute to eligible patients not receiving bariatric surgery once accepted onto the programme. Specified weight loss goals was the most significant barrier. Community support and online resources were significant enablers. This study should inform changes to bariatric programmes in New Zealand.
Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
This is a randomized controlled crossover trial of intubation with three laryngoscope devices in a neonatal manikin model. Level III NICU and PICU consultants, pediatric residents, anesthesiology consultants, and anesthesiology residents will be eligible to participate in the study. Participants in the ABC arm will be assigned to perform the intubation with a traditional laryngoscope (A), followed by the intubation with a straight blade video laryngoscope (B) and by the intubation with hyper-angulated video laryngoscope (C). Participants in different arms will be assigned to perform the intubations in different sequences (BCA/CAB/ACB/BAC/CBA). The primary outcome measure will be the forces applied to mannequin oro-tracheal tissues during intubation with the three kinds of tools. The secondary outcome measures will be the perceived workload during intubation and intubation time with the traditional laryngoscope and the video laryngoscope.
FIELD: medicine. SUBSTANCE: present invention relates to novel chemical compound of lithium with L-α- amino-γ- methylmercaptobutyric acid (L-methionine) which has antitumor and antiulcer activities in medicine. New class of chemical compounds have antitumor and antiulcer activities and are less toxic as compared with those known in the art. Said compound are prepared by synthesis in dimethylsulfoxide of L-α-amino-γ-lithium methylmercaptobutyrate having antitumor and antiulcer effects. Pharmacological tests show that L-α-amino - γ-lithium methylmercaptobutyrate shows antitumor and antiulcer activities, but unlike antitumor agents which are widely used, the above-mentioned compound is less toxic and causes no leukemia. EFFECT: improved properties of the title compound. 4 tbl
<P>PROBLEM TO BE SOLVED: To provide a cosmetic having low irritancy and excellent humectant effects.  <P>SOLUTION: The cosmetic comprises one or more kinds selected from the group consisting of lactic acid and a lactate and at least one kind of compound in the followings (A) to (C) and has pH4-8. A method for improving the humectant function of the cosmetic is carried out by regulating the pH of the cosmetic comprising the one or more kinds selected from the group consisting of the lactic acid and lactate to 4-8. (A) is an ingredient having antiinflammatory actions and (B) is a hyaluronic acid production promoting substance. (C) is an ingredient having excitometabolic actions.  <P>COPYRIGHT: (C)2004,JPO
Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine plus morphine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine.
Human brain aging is characterized by the production and deposition of β-amyloid (Aβ) in the form of senile plaques and cerebral amyloid angiopathy and the intracellular accumulation of hyper-phosphorylated tau (Hp-tau) to form neurofibrillary tangles (NFTs) and dystrophic neurites of senile plaques. The process progresses for years and eventually manifests as cognitive impairment and dementia in a subgroup of aged individuals. Aβ is produced and deposited first in the neocortex in most aged mammals, including humans; it is usually not accompanied by altered behavior and cognitive impairment. Hp-tau is less frequent than Aβ pathology, and NFTs are rare in most mammals. In contrast, NFTs are familiar from middle age onward in humans; NFTs first appear in the paleocortex and selected brain stem nuclei. NFTs precede for decades or years Aβ deposition and correlate with dementia in about 5% of individuals at the age of 65 and 25% at the age of 85. Based on these comparative data, (a) Aβ deposition is the most common Alzheimer's disease neuropathological change (ADNC) in the brain of aged mammals; (b) Hp-tau is less common, and NFTs are rare in most aged mammals; however, NFTs are the principal cytoskeletal pathology in aged humans; (c) NFT in aged humans starts in selected nuclei of the brain stem and paleocortical brain regions progressing to the most parts of the neocortex and other regions of the telencephalon; (d) human brain aging is unique among mammalian species due to the early appearance and dramatic progression of NFTs from middle age onward, matching with cognitive impairment and dementia in advanced cases; (e) neither mammalian nor human brain aging supports the concept of the amyloid cascade hypothesis.
PURPOSE:To provide a new cleaning agent effectively usable for cleaning tooth surface, containing, as abrasive ingredients, two kinds of hydroxyapatite differing in particle diameter from each other. CONSTITUTION:The objective cleaning agent containing, as abrasive ingredients, hydroxyapatite X 100-300mum in the maximum diameter and hydroxyapatite Y<=2mum in the maximum diameter. The above two kinds of hydroxyapatite X and Y are each at least one kind of amorphous hydroxyapatite baked or unbaked, independent of each other. In particular, the hydroxyapatite X, being high in hardness, is pref. of baked form, being pref. amorphous among others. The amounts of the hydroxyapatite X and hydroxyapatite Y to be contained are pref. 5-50 pts.wt. and 0.1-40 pts.wt. per 100 pts.wt. of the final cleaning agent. This cleaning agent preferably contains 30-60 pts.wt. of propylene glycol as humectant and 10-35 pts.wt. of polyvinylpyrrolidone having 500000-4000000 weight-average molecular weight as binder each per 100 pts.wt. of the final cleaning agent. This cleaning agent is useful for cleaning tooth surface.
PURPOSE:To obtain a novel inhibitory substance against an enzyme capable of converting angiotension I, by cultivating actinomycetes No937ZE-1 strain. CONSTITUTION:Actinomycetes No937ZE-1 strain(FERM-P7131) is separated from soil. This mold is cultivated aerobically in an ordinary liquid medium at 5-10pH at 15-35 deg.C, to yield an inhibitory substance against an enzyme capable of converting angiotensin I. This substance has the following physical and chemical properties. Constituent substance; phenylalanine and a ninhidrin-positive substance having approximately twice ratio of surface area as that of it by amino acid analyzer are contained in a hydrolyzate obtained by hydrolysis in 6N hydrochloric acid at 110 deg.C for 20hr. Melting point: not showing melting point at <=300 deg.C. Solubility: soluble in 0.1N aqueous solution of sodium hydroxide, slightly soluble in water and methanol, insoluble in ether, acetone, and n- hexane. Color reaction: positive in iodine reaction, negative in ninhydrin, and alpha- naphthol sulfate reaction.
The invention relates to repetitive human activity abnormal motion detection. Specifically, abnormal motion is detected in sensor data collected about the performance of repetitive human activity. An autoencoder network model is trained based on a standard active set. Repetitive activity is extracted from the sensor data. A first score is generated that indicates a distance of a repetition of the repetitive activity from the standard activity. Repetitive activities are used to retrain the auto-encoder network model, using as initial values the weights of the auto-encoder network model that are based on the training of the auto-encoder network model using the standard activity set. A second score is generated indicating whether the repeat is an outlier compared to other repeats of the repetitive activity. A final score is generated based on the weights of the first score and the second score.
Transparent aqueous cosmetic composition for cleaning of skin comprises at least one acyl isethionate and at least one protein hydrolyzate with hydrophobic group. The composition comprises: (i) at least one acyl isethionate; and (ii) at least one protein hydrolyzate with hydrophobic group, in amount required to solubilize acyl isethionate component. The amount of acyl isethionate is 0.5-15 wt.% and the amount of protein hydrolyzate is 0.5-30 wt.%. The weight content of active matter of protein hydrolyzate is at least equal to weight content of acyl isethionate. Composition contains 40-95 wt.% of water, preferably additionally contains nonionic surfactant, and preferably has form of transparent gel. An Independent claim is also included for removing make-up and/or cleaning of skin, hair, lips and/or eyes, by applying the above composition.
PURPOSE:An arteriosclerotic agnet, containing a freeze-dried substance containing egg yolk and vitamin C in given specified amounts as principal components, and capable of increasing a high density lipoprotein (HDL) cholesterol in blood and reducing the arteriosclerotic index. CONSTITUTION:An arteriosclerotic agent containing 2,200pts.wt. egg yolk (on the dry basis) and 1-70pts.wt. vitamin C (on the dry basis) as principal components. If the content of a high density lipoprotein (HDL) cholesterol in blood is reduced, low density lipoprotein (LDL) cholesterol and very low density lipoprotein  (VLDL) cholesterol have an increasing tendency to deposit on the blood vessel wall simultaneously to cause the arteriosclerosis. The incorporation of the vitamin C with the egg yolk activates an enzyme known as 7alpha-hydroxycholesterol, accelerated. Thus, the LDL cholesterol and VLDL cholesterol are reduced to increase the HDL cholesterol.
The intestine is the largest immune organ in the human body, playing a crucial role in regulating host health, maintaining metabolic and immune homeostasis, and preventing pathogen invasion. The gut microbiota can directly participate in the immune regulation of the host, promote the development of the immune system, and maintain normal immune function. Meanwhile, the immune system also has a regulatory and constraining effect on the gut microbiota. With age, the structure of the gut microbiota and the function of the immune system undergo continuous changes and adjustments to adapt to the body's needs. This dynamic gut microbiota-immune system interaction plays a key role in maintaining metabolic homeostasis and immune balance in the body.Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, commonly seen in middle-aged and elderly individuals. MM patients generally have a higher risk of infection, especially after receiving intensive chemotherapy or hematopoietic stem cell transplantation.Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic condition, and multiple myeloma often progresses from monoclonal gammopathy. Although most MGUS patients do not progress to malignant disease for life, MGUS patients do have a higher risk of infection. Gut microbiome dysbiosis may be involved in regulating immune function, leading to increased susceptibility to infections in MGUS patients.This study aims to use a retrospective cohort study approach to systematically analyze the characteristics of the gut microbiota in MGUS patients with concurrent infections, and explore its correlation with immune-related indicators. In-depth analysis of these key factors will help further elucidate the pathogenesis of MGUS complicated by infection, and provide new evidence and insights for clinical prevention and treatment.
Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
This invention discloses a peptide, which inhibits the interaction between of MZF-1 and Elk-1 and further inhibits cancers. Both myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) expressions correlate to PKC[alpha] expression in cancer cells. Furthermore, it is the interaction between the acidic domain of MZF-1 and the heparin-binding domain of Elk-1 which facilitated their heterodimeric complex formation before their binding to the PKC[alpha] promoter. Blocking the formation of the heterodimer changed Elk-1 nuclear localization, MZF-1 protein degradation, their DNA-binding activities, and subsequently the expression of PKC[alpha] in cancer cells. Thus, migration, tumorigenicity, and epithelial-mesenchymal transition potential of cancer cells decreased, suggesting that the Elk-1/MZF-1 heterodimer is considered as a mediator of PKC[alpha] in TNBC cell malignancy. The obtained data also suggest that the next therapeutic strategy in the treatment of cancer will come from the blocking of Elk-1/MZF-1 interaction through the saturation of Elk-1 or MZF-1 binding domains, such as through the application of cell-penetrating HIV transactivating regulatory protein-fused peptides.
To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.

Alkalinization of urine hastens phenobarbital excretion, but dialysis and hemoperfusion are more effective and cause less troublesome alteration in electrolyte equilibrium. If the patient has chronically abused sedatives, withdrawal reactions may be manifest following acute overdose.
According to one embodiment, a medical image processing apparatus includes an image obtaining unit, a three-dimensional medical image generating unit, a correction information obtaining unit, a display angle correcting unit, and a display unit. The image obtaining unit obtains medical image data including an object. The three-dimensional medical image generating unit generates stereoscopic three-dimensional medical image data including a plurality of objects based on the medical image data obtained by the image obtaining unit. The correction information obtaining unit obtains correction information for the plurality of objects. The display angle correcting unit corrects, based on the correction information, the three-dimensional medical image data so that a display angle of at least one of the plurality of objects is corrected. The display unit displays a three-dimensional medical image based on the three-dimensional medical image data corrected by the display angle correcting unit.
The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (\<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (\<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
Choroidal atrophy is a common fundus pathological change closely related to the development of age-related macular degeneration (AMD), retinitis pigmentosa, and pathological myopia. Studies suggest that choroidal endothelial cells (CECs) that form the choriocapillaris vessels are the first cells lost in choroidal atrophy. It is found that endothelial cells derived from human pluripotent stem cells (hPSC-ECs) through the MESP1+ mesodermal progenitor stage express CECs-specific markers and can integrate into choriocapillaris. Single-cell RNA-seq (scRNA-seq) studies show that hPSC-ECs upregulate angiogenesis and immune-modulatory and neural protective genes after interacting with ex vivo ischemic choroid. In a rat model of choroidal ischemia (CI), transplantation of hPSC-ECs into the suprachoroidal space increases choroid thickness and vasculature density. Close-up examination shows that engrafted hPSC-ECs integrate with all layers of rat choroidal vessels and last 90 days. Remarkably, EC transplantation improves the visual function of CI rats. The work demonstrates that hPSC-ECs can be used to repair choroidal ischemia in the animal model, which may lead to a new therapy to alleviate choroidal atrophy implicated in dry AMD, pathological myopia, and other ocular diseases.
Mesenchymal stem cells/stromal cells (MSCs)-derived extracellular vesicles (EVs) mediate pro-regenerative effects in damaged ischemic tissues by regulating angiogenesis. MSCs-EVs modulate functions of cells including endogenous mature cells, progenitors and stem cells, resulting in restoration of blood flow. However, the mechanisms underlying such MSC-EV activity still remain poorly understood. The present study analyzes biological effects of bone marrow (BM) MSC-EVs on endothelial cells (ECs) in ischemic tissues both in in vitro and in vivo conditions and elucidates the molecular mechanisms underlying the tissue repair. MSC-EVs were isolated from murine BM-derived MSCs and their morphological, antigenic and molecular composition regarding protein and microRNA levels were evaluated to examine their properties. Global proteomic analysis demonstrated the presence in MSC-EVs of proteins regulating pro-regenerative pathways, including integrin α5 (Itgα5) and neuropilin-1 (NRP1) involved in lymphangiogenesis. MSC-EVs were also enriched in microRNAs regulating angiogenesis, TGF-β signaling and processes guiding cellular adhesion and interactions with extracellular matrix. The functional effects of MSC-EVs on capillary ECs in vitro included the increase of capillary-like tube formation and cytoprotection under normal and inflammatory conditions by inhibiting apoptosis. Notably, MSC-EVs enhanced also capillary-like tube formation of lymphatic ECs, which may be regulated by Itgα5 and NRP1. Moreover, in a mouse model of critical hind limb ischemia, MSC-EVs increased the recovery of blood flow in ischemic muscle tissue, which was accompanied with increased vascular density in vivo. This pro-angiogenic effect was associated with an increase in nitric oxide (NO) production via endothelial NO-synthase activation in ischemic muscles. Interestingly, MSC-EVs enhanced lymphangiogenesis, which has never been reported before. The study provides evidence on pro-angiogenic and novel pro-lymphangiogenic role of MSC-EVs on ECs in ischemic tissue mediated by their protein and miRNA molecular cargos. The results highlight Itgα5 and NRP1 carried by MSC-EVs as potential therapeutic targets to boost lymphangiogenesis.
Resistance training (RT) is recommended to people with different health condition. RT is recognized as safe and effective method of increasing muscle strength, physical fitness, muscle mass, and overall cardiovascular health. The magnitude of the RT effects is associated with the structure of the training program. Understanding these aspects may provide guidance for the RT prescription while reducing potential risk of cardiovascular events associated with the recovery period after exercise. The objective of the study is to compare the acute responses of the Autonomic Nervous System post RT performed with different intensities (endurance and strength) in different body segments (UL and LL). Our hypothesis is that different intensities and body segments influence the acute responses of the ANS in the post RT recovery period.
Angiosperms, which inhabit diverse environments across all continents, exhibit significant variation in genome sizes, making them an excellent model system for examining hypotheses about the global distribution of genome size. These include the previously proposed large genome constraint, mutational hazard, polyploidy-mediated, and climate-mediated hypotheses. We compiled the largest genome size dataset to date, encompassing 16 017 (> 5% of known) angiosperm species, and analyzed genome size distribution using a comprehensive geographic distribution dataset for all angiosperms. We observed that angiosperms with large range sizes generally had small genomes, supporting the large genome constraint hypothesis. Climate was shown to exert a strong influence on genome size distribution along the global latitudinal gradient, while the frequency of polyploidy and the type of growth form had negligible effects. In contrast to the unimodal patterns along the global latitudinal gradient shown by plant size traits and polyploid proportions, the increase in angiosperm genome size from the equator to 40-50°N/S is probably mediated by different (mostly climatic) mechanisms than the decrease in genome sizes observed from 40 to 50°N northward. Our analysis suggests that the global distribution of genome sizes in angiosperms is mainly shaped by climatically mediated purifying selection, genetic drift, relaxed selection, and environmental filtering.
The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10\^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if \> 30 kg) IV over 60 minutes) every 4 weeks.